Tag Archives: Komal Jhaveri

(IN BRIEF) AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has gained approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer possessing specific … Read the full press release →